Additionally, previous studies indicated that the occurrence of a primary T790M mutation was associated with worse response and poor prognosis in patients with advanced EGFR-m NSCLC treated with first-generation (26–29), and second-generation (30, 31) EGFR-TKIs. Here, EGFR is linked to non-small cell lung carcinoma.